Terms: = Breast cancer AND CDX2, CDX3, 1045, ENSG00000165556, Q99626 AND Treatment
29 results:
1. H4K20me3, H3K4me2 and H3K9me2 mediate the effect of ER on prognosis in breast cancer.
Xiao CK; Ren Y; Chen Q; Yang Y; Tang L; Xu L; Ren Z
Epigenetics; 2024 Dec; 19(1):2343593. PubMed ID: 38643489
[TBL] [Abstract] [Full Text] [Related]
2. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.
Grinda T; Antoine A; Jacot W; Cottu PH; de la Motte Rouge T; Frenel JS; Mailliez A; Dalenc F; Goncalves A; Clatot F; Mouret Reynier MA; Levy C; Ferrero JM; Desmoulins I; Uwer L; Petit T; Jouannaud C; Arnedos M; Chevrot M; Courtinard C; Tredan O; Brain E; Pérol D; Pistilli B; Delaloge S
Eur J Cancer; 2023 Aug; 189():112935. PubMed ID: 37385070
[TBL] [Abstract] [Full Text] [Related]
3. Urachal carcinoma: The journey so far and the road ahead.
Kumar R; Harilal S; Abdelgawad MA; Ghoneim MM; Kumar A; Mathew B
Pathol Res Pract; 2023 Mar; 243():154379. PubMed ID: 36821941
[TBL] [Abstract] [Full Text] [Related]
4. [Clinicopathological analysis of lung metastatic tumor].
Lou N; Niu YR; Yang F; Lu ZH
Zhonghua Bing Li Xue Za Zhi; 2021 Sep; 50(9):1039-1044. PubMed ID: 34496496
[No Abstract] [Full Text] [Related]
5. cdx2-positive breast cancer presented with axillary lymph node metastases: A case report.
Hoshina H; Takei H; Sakatani T; Naito Z
Cancer Treat Res Commun; 2021; 26():100300. PubMed ID: 33421821
[TBL] [Abstract] [Full Text] [Related]
6. A retrospective analysis to demonstrate achievable dosimetry for the left anterior descending artery in left-sided breast cancer patients treated with radiotherapy.
Quirk S; Grendarova P; Phan T; Conroy L; Burke B; Long K; Thind K; Cao J; Craighead P; Olivotto IA; Roumeliotis M
Radiother Oncol; 2020 Jul; 148():167-173. PubMed ID: 32388151
[TBL] [Abstract] [Full Text] [Related]
7. breast metastasis from rectal cancer with BRAF V600E mutation: a case report with a review of the literature.
Hasegawa H; Nagata Y; Sakakibara Y; Miyake M; Mori K; Masuda N; Mano M; Nakazuru S; Ishida H; Mita E
Clin J Gastroenterol; 2020 Apr; 13(2):153-157. PubMed ID: 31482523
[TBL] [Abstract] [Full Text] [Related]
8. Vitamin D Receptor Genetic Variation and cancer Biomarkers among breast cancer Patients Supplemented with Vitamin D3: A Single-Arm Non-Randomized Before and After Trial.
Kazemian E; Akbari ME; Moradi N; Gharibzadeh S; Mondul AM; Jamshidi-Naeini Y; Khademolmele M; Zarins KR; Ghodoosi N; Amouzegar A; Davoodi SH; Rozek LS
Nutrients; 2019 Jun; 11(6):. PubMed ID: 31167402
[TBL] [Abstract] [Full Text] [Related]
9. Immunohistochemical profiles in primary lung cancers and epithelial pulmonary metastases.
Vidarsdottir H; Tran L; Nodin B; Jirström K; Planck M; Jönsson P; Mattsson JSM; Botling J; Micke P; Brunnström H
Hum Pathol; 2019 Feb; 84():221-230. PubMed ID: 30389437
[TBL] [Abstract] [Full Text] [Related]
10. Alternative Polyadenylation Patterns for Novel Gene Discovery and Classification in cancer.
Begik O; Oyken M; Cinkilli Alican T; Can T; Erson-Bensan AE
Neoplasia; 2017 Jul; 19(7):574-582. PubMed ID: 28624626
[TBL] [Abstract] [Full Text] [Related]
11. Incidental breast carcinoma in reduction mammoplasty.
Huysmans M; Bronckaers M; Schillebeeckx C; Servaes D
Acta Chir Belg; 2017 Oct; 117(5):308-311. PubMed ID: 28610472
[TBL] [Abstract] [Full Text] [Related]
12. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Cameron D; Morden JP; Canney P; Velikova G; Coleman R; Bartlett J; Agrawal R; Banerji J; Bertelli G; Bloomfield D; Brunt AM; Earl H; Ellis P; Gaunt C; Gillman A; Hearfield N; Laing R; Murray N; Couper N; Stein RC; Verrill M; Wardley A; Barrett-Lee P; Bliss JM;
Lancet Oncol; 2017 Jul; 18(7):929-945. PubMed ID: 28600210
[TBL] [Abstract] [Full Text] [Related]
13. Surgical treatment for mediastinal parathyroid adenoma causing primary hyperparathyroidism.
Kitada M; Yasuda S; Nana T; Ishibashi K; Hayashi S; Okazaki S
J Cardiothorac Surg; 2016 Apr; 11():44. PubMed ID: 27056365
[TBL] [Abstract] [Full Text] [Related]
14. cdx2 as a Prognostic Biomarker in Stage II and Stage III Colon cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract] [Full Text] [Related]
15. cdx2 polymorphism affects the activities of vitamin D receptor in human breast cancer cell lines and human breast carcinomas.
Pulito C; Terrenato I; Di Benedetto A; Korita E; Goeman F; Sacconi A; Biagioni F; Blandino G; Strano S; Muti P; Mottolese M; Falvo E
PLoS One; 2015; 10(4):e0124894. PubMed ID: 25849303
[TBL] [Abstract] [Full Text] [Related]
16. Uveal melanoma: A pathologist's perspective and review of translational developments.
Schoenfield L
Adv Anat Pathol; 2014 Mar; 21(2):138-43. PubMed ID: 24508696
[TBL] [Abstract] [Full Text] [Related]
17. Delayed metastasis to the mandible of esophageal adenocarcinoma.
Lawes KP; Danford M; Di Palma S
Head Neck Pathol; 2013 Dec; 7(4):416-20. PubMed ID: 23740162
[TBL] [Abstract] [Full Text] [Related]
18. [Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer].
Chiba A; Shimizu S; Yoshida A; Inaba M; Matsuura H; Ino H; Suganuma N; Inari H; Yamanaka T; Kuroda K; Mukaibashi T; Matsuo A; Kojima I
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1675-9. PubMed ID: 23152018
[TBL] [Abstract] [Full Text] [Related]
19. Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.
Lalisang RI; Erdkamp FL; Rodenburg CJ; Knibbeler-van Rossum CT; Nortier JW; van Bochove A; Slee PH; Voest EE; Wils JA; Wals J; Loosveld OJ; Smals AE; Blijham GH; Tjan-Heijnen VC; Schouten HC
Breast Cancer Res Treat; 2011 Jul; 128(2):437-45. PubMed ID: 21584666
[TBL] [Abstract] [Full Text] [Related]
20. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.
Farabegoli F; Papi A; Orlandi M
Biosci Rep; 2011 Apr; 31(2):99-108. PubMed ID: 20446926
[TBL] [Abstract] [Full Text] [Related]
[Next]
